These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. Marcus SM; Gorman J; Shear MK; Lewin D; Martinez J; Ray S; Goetz R; Mosovich S; Gorman L; Barlow D; Woods S Am J Psychiatry; 2007 Feb; 164(2):273-5. PubMed ID: 17267790 [TBL] [Abstract][Full Text] [Related]
4. Cost-efficacy of individual and combined treatments for panic disorder. McHugh RK; Otto MW; Barlow DH; Gorman JM; Shear MK; Woods SW J Clin Psychiatry; 2007 Jul; 68(7):1038-44. PubMed ID: 17685740 [TBL] [Abstract][Full Text] [Related]
5. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313 [TBL] [Abstract][Full Text] [Related]
6. Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Furukawa TA; Katherine Shear M; Barlow DH; Gorman JM; Woods SW; Money R; Etschel E; Engel RR; Leucht S Depress Anxiety; 2009; 26(10):922-9. PubMed ID: 19006198 [TBL] [Abstract][Full Text] [Related]
7. Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy. Aaronson CJ; Shear MK; Goetz RR; Allen LB; Barlow DH; White KS; Ray S; Money R; Saksa JR; Woods SW; Gorman JM J Clin Psychiatry; 2008 Mar; 69(3):418-24. PubMed ID: 18278989 [TBL] [Abstract][Full Text] [Related]
8. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Mavissakalian MR; Perel JM Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Nations KR; Smits JA; Tolin DF; Rothbaum BO; Hofmann SG; Tart CD; Lee A; Schipper J; Sjogren M; Xue D; Szegedi A; Otto MW J Clin Psychiatry; 2012 May; 73(5):647-53. PubMed ID: 22394471 [TBL] [Abstract][Full Text] [Related]
10. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Simon NM; Otto MW; Worthington JJ; Hoge EA; Thompson EH; Lebeau RT; Moshier SJ; Zalta AK; Pollack MH J Clin Psychiatry; 2009 Nov; 70(11):1563-70. PubMed ID: 19814948 [TBL] [Abstract][Full Text] [Related]
11. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Loerch B; Graf-Morgenstern M; Hautzinger M; Schlegel S; Hain C; Sandmann J; Benkert O Br J Psychiatry; 1999 Mar; 174():205-12. PubMed ID: 10448444 [TBL] [Abstract][Full Text] [Related]
12. Panic disorder: long-term pharmacotherapy and discontinuation. Rickels K; Schweizer E J Clin Psychopharmacol; 1998 Dec; 18(6 Suppl 2):12S-18S. PubMed ID: 9872708 [TBL] [Abstract][Full Text] [Related]
13. Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. Bergström J; Andersson G; Ljótsson B; Rück C; Andréewitch S; Karlsson A; Carlbring P; Andersson E; Lindefors N BMC Psychiatry; 2010 Jul; 10():54. PubMed ID: 20598127 [TBL] [Abstract][Full Text] [Related]
14. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Roy-Byrne PP; Craske MG; Stein MB; Sullivan G; Bystritsky A; Katon W; Golinelli D; Sherbourne CD Arch Gen Psychiatry; 2005 Mar; 62(3):290-8. PubMed ID: 15753242 [TBL] [Abstract][Full Text] [Related]
15. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Mavissakalian MR; Perel JM Ann Clin Psychiatry; 2001 Jun; 13(2):63-7. PubMed ID: 11534926 [TBL] [Abstract][Full Text] [Related]
16. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. Sheikh JI; Swales PJ Int J Psychiatry Med; 1999; 29(1):107-17. PubMed ID: 10376237 [TBL] [Abstract][Full Text] [Related]
17. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Mavissakalian MR; Perel JM J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900 [TBL] [Abstract][Full Text] [Related]
18. Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. Hicks TV; Leitenberg H; Barlow DH; Gorman JM; Shear MK; Woods SW J Consult Clin Psychol; 2005 Jun; 73(3):506-14. PubMed ID: 15982148 [TBL] [Abstract][Full Text] [Related]
19. Imipramine for vestibular dysfunction in panic disorder: a prospective case series. Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560 [TBL] [Abstract][Full Text] [Related]
20. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. van Apeldoorn FJ; van Hout WJ; Mersch PP; Huisman M; Slaap BR; Hale WW; Visser S; van Dyck R; den Boer JA Acta Psychiatr Scand; 2008 Apr; 117(4):260-70. PubMed ID: 18307586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]